5-CNAC as oral delivery agent for parathyroid hormone fragments

Details for Australian Patent Application No. 2002333443 (hide)

Owner Novartis AG

Inventors Bateman, Simon David; Azria, Moise

Agent Davies Collison Cave

Pub. Number AU-B-2002333443

PCT Number PCT/EP02/09181

PCT Pub. Number WO2003/015822

Priority 60/313,048 17.08.01 US

Filing date 16 August 2002

Wipo publication date 3 March 2003

Acceptance publication date 29 June 2006

International Classifications

A61K 47/18 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

A61K 38/29 (2006.01) Medicinal preparations containing peptides - Parathyroid hormone (parathormone)

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

Event Publications

13 February 2003 Complete Application Filed

  Priority application(s): 60/313,048 17.08.01 US

29 May 2003 Application Open to Public Inspection

  Published as AU-B-2002333443

29 June 2006 Application Accepted

  Published as AU-B-2002333443

26 October 2006 Standard Patent Sealed

8 October 2009 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 25 Mar 2009 2003

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002333444-NANOPARTICLES COMPRISING BIOLOGICALLY ACTIVE TNF WHICH IS IMMOBILISED ON THE SAME

2002333442-DEVICE FOR THE DELIVERY AND RECEIPT OF ITEMS OF WASHING